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A BST R AC T   
 
Aim: We visually and quantitatively investigated the success of using 2-deoxy-2-[fluorine-18] fluoro-D-
glucose integrated with computed tomography (18F-FDG PET/CT) and magnetic resonance imaging (MRI) 
[Dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI)] separately and together in 
detecting axillary lymph node metastasis in patients with newly diagnosed breast cancer. 
Methods: One hundred and thirteen patients who underwent 18F FDG PET/CT were evaluated, 102 patients 
of these patients had also MRI (DEC + DWI). Primary tumour size (Tsize), SUVmax of primary tumour 
(SUVmaxT), short diameter of largest axillary lymph node on PET/CT (LnDPET/CT), SUVmax of axillary 
lymph node (SUVmaxLn), metabolic tumour volume of the primary tumour (MTV), short diameter of largest 
axillary lymph node on MRI (LnDMRI), the presence of fatty hilum absence and apparent diffusion coefficient 
(ADC) were evaluated.  
Results: In visual analysis, sensitivity and specificity values of 18F FDG PET/CT, MRI and MRI+18F FDG 
PET/CT were 78.85, 94% – 72.27%, 96.15 – 83.87%, 98.04%, respectively. In the quantitative evaluation, 
ADC≤1.2 x 10-3 mm2/sec (OR = 6.665, p = 0.001, 95CI%: 2.181–20.370) and LnSUVmax> 2 (OR = 15.2, 
p<0.001, 95CI%: 4.587–50.376) were independent predictors in detecting axillary lymph node metastasis.  
Conclusion: LnSUVmax >2 and ADC ≤ 1.2 x 10-3 mm2/sec can be used as independent predictors of detecting 
axillary lymph node metastasis in patients with newly diagnosed breast cancer. 
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Introduction 
The presence of axillary lymph node metastasis 
(ALNM) is important for the prognosis of 
breast cancer and has an impact on treatment 
management [1]. Sentinel lymph node biopsy 
(SLNB) has become the standard axilla staging 
procedure in patients with early stage breast 
cancer due to its lower morbidity rate and 
similar accuracy compared to axillary lymph 
node dissection (ALND) [2]. However, SLNB 
requires preoperative lymphoscintigraphy and a 
detailed pathological examination. In addition, 
it is a time-consuming complicated process [3]. 
Although SLNB has high sensitivity and 
specificity values in detecting axillary 
metastatic lymph node in breast cancer patients 
[4], it has also been reported to give false 
negative results [5-7]. It is an invasive 
procedure with complications such as infection, 
lymphedema and seroma [8]. For these reasons, 
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it is important to evaluate the axillary lymph 
node metastasis status by non-invasive imaging 
methods before surgery in patients with breast 
cancer [9, 10].  
In addition to detecting the presence of distant 
organ metastasis in patients with breast cancer, 
2-deoxy-2-[fluorine-18] fluoro-D-glucose 
integrated with computed tomography (18F 
FDG PET/CT), which shows the glucose 
metabolism of the tissue, provides valuable 
information in detecting axillary lymph node 
metastasis.  High sensitivity and specificity 
values have been reported for the success of 18F 
FDG PET/CT in detecting metastatic lymph 
nodes in the axilla in patients with breast cancer 
[9, 11, 12].  
Another non-invasive imaging method, 
magnetic resonance imaging (MRI), which is 
applied with dynamic contrast enhancement 
(DCE) and the diffusion-weighted imaging 
(DWI) technique, is used to evaluate the 
presence of axilla lymph node metastasis in 
patients with breast cancer [13, 14]. High 
sensitivity and specificity values of MRI 
applied with these two techniques have been 
reported in detecting axillary metastatic lymph 
nodes in breast cancer patients [15-17]. 
In this study, we investigated the success of 
each and their combined use of 18F FDG 
PET/CT and DCE/DWI-MRI in detecting 
axillary metastatic lymph nodes in patients with 
newly diagnosed breast cancer  
 
Materials and methods 
The Clinical Research Ethics Committee of our 
institute reviewed and approved this 
retrospective study (2019/136). As this was a 
retrospective study, it was exempt by the 
institutional review board from the need for 
informed consent. All procedures performed in 
studies involving human participants were in 
accordance with the Helsinki declaration.  
Patient selection: We retrospectively reviewed 
the data of patients diagnosed with breast 
cancer between March 2017 and January 2019 
and who underwent 18F FDG PET/CT and MRI 
before treatment. We included 113 patients who 
underwent 18F FDG PET/CT, 102 of these 
patients also had MRI. We did not include 
patients who received neoadjuvant therapy. All 
patients had undergone SLNB or ALND. We 
included patients with invasive ductal 
carcinoma. 
Surgical method: SLNB was applied to 60 
patients who were clinically and radiologically 
axillary lymph node metastasis free; ALND 
was applied to 79 patients. Axillary dissection 
was performed in 53 of these patients whose 
axilla was clinically and radiologically 
metastatic. In 9 of these patients, the frozen 
result was positive for metastasis, while the 
frozen result was suspicious in terms of 
metastasis in 3 of them. In 3 patients, ALND 
was performed due to the detection of 
suspicious lymph nodes intraoperatively and in 
11 patients due to the absence of sentinel lymph 
nodes (N = 26). 
Nuclear medicine method 
(lymphoscintigraphy) was not used for SLNB. 
After the injection of "isosulfan blue" 
into/around the tumour or around the nipple, the 
lymph nodes which were stained blue in the 
axilla were excised. 
18F‐FDG PET/CT procedures: A PET/CT 
scanner Biograph mCT (Siemens Healthcare, 
Erlangen, Germany) was used. After at least 4 
hours of fasting, patients with a blood glucose 
level of < 200 mg/dl were administered a FDG 
injection at an approximate dose of 3.7 
MBq/kg. After median 61 minutes [min-max 
52-81 minutes], imaging was performed in the 
supine position with arms up. The PET imaging 
was adjusted to 2 minutes per bed position. 
Low-dose CT parameters were as follows: 
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voltage, 120 kV, CARE Dose 4D mA tube 
current and slice thickness 5.00 mm. 
18F‐FDG PET/CT parameters: We evaluated 
the long diameter of the primary tumour 
(Tsize), the maximum standardised uptake 
value of the primary tumour normalised to body 
weight (SUVmaxT), the short diameter of the 
axillary lymph node (LnDPET/CT), the 
maximum standardised uptake value of the 
axillary lymph node normalised to body weight 
(SUVmaxLn), the metabolic tumour volume of 
the primary tumour according to the 40% 
threshold of the SUVmaxT (MTV) and the 
presence of multifocality of the primary 
tumour. 
18F FDG PET/CT image analyses: The 
Siemens Healthhineers Syngo.via VB30 
workstation, MM Oncology, post-processing 
unit was used for analyses. All analyses were 
performed by a Nuclear Medicine Specialist 
(O.K.) with 9 years of PET/CT experience. 
MRI procedure: Magnetic Resonance imaging 
was performed on a 3 Tesla MR (Discovery 
w750, GE Healthcare, United States) device 
with an 8-channel breast coil in the prone 
position. Following conventional images, 
diffusion-weighted images and pre-contrast 
images, dynamic images were obtained by 
intravenous injection of contrast material 
through the antecubital vein.  
For all patients, T2-weighted (FSE-IDEAL) 
axial section (time to repetition (TR)/TE: 
7127/85 ms; section thickness 3.5 mm; field of 
view (FOV) 400 mm), T1-weighted (FSE) axial 
section (TR/TE: 838 ms/12 ms; slice thickness 
3.5 mm; FOV: 400 mm), STIR axial section 
(TR/TE: 7673 ms/32 ms; TI: 180 ms; slice 
thickness 3.5 mm; FOV: 400 mm) were 
obtained. 
The DWI was obtained at two different b values 
(50 s/mm², 800 s/mm²) with the echo-planar SE 
T2 weighted sequence (TR/TE: 6193 ms/18 ms; 
cross sectional area 4 mm; FOV: 400 mm) in 
the axial plane. For DCE, gadobutrol 
(Gadovist; Bayer Schering Pharma, Berlin, 
Germany) was administered intravenously at a 
dose of 0.1 mmol/kg with an automatic injector 
at a speed of 3 ml/sec, and high-resolution T1-
weighted oil-suppressed TSE axial and sagittal 
section (TR/TE: 5 ms /2.3 ms; slice thickness 
0.8 mm; FOV: 360 mm, flip angle: 10) images 
were obtained. The DCE sequence was 
performed by axial imaging obtained at 70, 130, 
190, 250 and 310 seconds in pre-contrast and 
post-contrast dynamic series. 
MRI parameters: We evaluated the short 
diameter of axillary lymph nodes and the 
presence of fatty hilum absence. The ADC 
values were measured. 
MRI image analysis: The MRI images of the 
patients were evaluated without knowing the 
pathology results and PET/CT findings. All 
analyses were performed by a Radiologist 
(H.G.) with 8 years of MRI experience. 
ADC measurement technique: Lymph nodes 
with contrast enhancement in DCE and higher 
signal intensity in DWI were detected in the 
axilla. We then manually drew ROIs from 3 
sections with a standard area of 0.25-0.35 mm2 
on the relevant region on the ADC map and 
obtained the mean ADC values.  
The median time between 18F FDG PET/CT 
and MRI was 3 days [min: 0, max: 10]. There 
was a median of 11 days (minimum: 2, 
maximum: 29) between MRI and axillary 
surgery and a median of 9 days (min: 3, max: 
22) between 18F FDG PET/CT and axillary 
surgery. 
Statistical analysis: Continuous demographic 
data were analysed according to normality tests. 
Parametric data were reported as mean ± 
standard deviation and non-parametric data as 
median (min-max). Differences between 
groups were analysed using Student's t-test in 
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parametric data and Mann-Whitney U tests in 
non-parametric data. Discontinuous variables 
were shown as frequency. We used receiver 
operating characteristic (ROC) curve analysis 
to evaluate the diagnostic performance of the 
methods and to determine the threshold value. 
Univariate and multivariate logistic regression 
analyses were used to determine the 
relationship of test parameters of the patients at 
risk for axillary lymph node metastasis. 
Statistical significance value was accepted as 
0.05. The software package SPSS v. 25 




In total, 113 female patients (mean age: 55.6 
standard deviation (SD): 13.36) who were 
diagnosed with breast cancer and underwent 18F 
FDG PET/CT were evaluated. One hundred and 
two of theese patients also had MRI Of these, 
97 patients were luminal, 6 patients were Her2-
positive, and 10 patients were in the triple 
negative (TN) receptor subgroup. The presence 
of axillary lymph node metastasis was 
confirmed histopathologically in 58 patients. 
Axillary lymph node metastasis was not 
detected in 55 patients. Patient and tumour 
characteristics are given in Tables 1 and 2. 
Visual analysis: We performed visual analysis 
in 102 patients who underwent both 18F FDG 
PET/CT and MRI. Histopathological metastasis 
was detected in 52 of these patients; metastasis 
was not detected in 50 patients. The 18F FDG 
PET/CT detected 41 (79%) of 52 patients with 
axillary lymph node metastasis and failed to 
detect axillary lymph node metastasis in 11 
patients (21%). The mean value of the short 
diameter in the lymph nodes of 11 patients in 
whom 18F FDG PET/CT could not detect 
axillary lymph node metastasis was 5.14 ± 0.9 










































Table 1. Mean-median values of parameters 
evaluated by MRI and 18F FDG PET/CT. 
Parameters Mean ± SD    Median  
 [Min-Max] 
ADC (mm2/sec) 1.18 ± 0.27 1.21 (0.65-2.1) 
LnDMRI (mm) 9 ± 5 8 (4-32) 
LnDPET/CT 
(mm) 
8 ± 5 7 (3-32) 
LnSUVmax 3.63 ± 4.46 1.40 (0.50-19.3) 
MTV (cm3) 6.07 ± 7.63 3.70 (0.40-55) 
SUVmaxT 9.49 ± 9.11 6.95 (1.30-73.5) 
Tsize (mm) 23 ± 11 21 (8-60) 
 
ADC, apparent diffusion coefficient; MTV, metabolic 
tumour volume; LnDMRI, short diameter of the 
largest axillary lymph node measured by MRI; 
LnDPET/CT, short diameter of the largest axillary 
lymph node measured by PET/CT; LnSUVmax, 
SUVmax of the axillary lymph node; SUVmaxT, 
SUVmax of the primary tumour; Tsize, long diameter 
of the primary tumour. 
 
Table 2. Tumour characteristics. 
Parameters N / % 
ALNM 
















ALNM, Axillary lymph node metastasis status 
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The 18F FDG PET/CT was false positive in 3 of 
50 patients (6%) without axilla lymph node 
metastasis. In 47 patients (94%), 18F FDG 
PET/CT was able to detect no axillary lymph 
node metastasis. For the axillary lymph node 
short diameter > 6 mm, we found a 79% 
sensitivity of 18F FDG PET/CT to detect the 
presence of metastasis, with a specificity of 





















Magnetic resonance imaging (DCE + DWI) 
was performed in 102 patients and detected 30 
(57.7%) of 52 patients with lymph node 
metastasis. The short-diameter mean value of 
lymph nodes of 22 patients in whom MRI could 
not detect lymph node metastasis was 7.1mm ± 
1.16 [min: 5 mm, max: 9 mm]. The MRI 
detected 48 (96%) of 50 patients without 
axillary lymph node metastasis and was false 
positive in only 2 patients (4%). 
When 18F FDG PET/CT and MRI results were 
evaluated together (n = 102), 18F FDG PET/CT 
+ MRI detected 42 (81%) of 52 patients with 
axillary lymph node metastasis, but could not 
detect 10 patients (19%). Short-diameter mean 
values of lymph nodes in these 10 patients were 
5 ± 0.9 mm and 6.5 ± 0.85 mm for 18F FDG 
PET/CT and MRI, respectively. The MRI + 18F 
FDG PET/CT detected 49 (98%) of 50 patients 
without axillary lymph node metastasis, with a 
false positive result in only 1 patient. The 
efficiency of the ROC curve of 18F FDG 
PET/CT, MRI and MRI + 18F FDG PET/CT in 
detecting axillary metastatic lymph nodes is 
given in Figure 2. The sensitivity, specificity, 
accuracy, positive predictive values and 
negative predictive values of each of the 18F 
FDG PET/CT, MRI, 18F FDG PET/CT + MRI 
in detecting axillary metastatic lymph nodes are 





















Quantitative analysis: We evaluated the MRI 
parameters [ADC, LnDMRI, fatty hilum 
absence] of 102 patients in univariate logistic 
regression analysis. In detecting lymph node 
metastasis, we performed ROC analysis and set  
      
 
Figure 1. ROC curve showing the success of 18F 
FDG PET/CT in detecting axillary metastatic lymph 
nodes when adopting a 6-mm threshold value for 
lymph node short diameter. 
 
 
Figure 2. ROC curve demonstrating the success of 
18F FDG PET/CT, MRI and MRI + 18F FDG PET/CT 
in detecting axillary metastatic lymph nodes. 
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a threshold value of 1.2 x 10-3 mm2/sec to obtain 
optimal sensitivity and specificity values for 
ADC. In univariate analysis, LnDMRI (Odds 
Ratio (OR) = 1.254, p = 0.01, 95% CI: 1.056-
1.489), ADC ≤ 1.2 x 10-3 mm2/sec (OR = 
10.815, p < 0.001, 95CI%: 4.223-27.701) and 
lymph node fatty hilum absence (OR: 18, p < 
0.001, 95CI%: 4.937-65.623) were statistically 
significant predictors for detecting axillary 

































Multivariate logistic regression analysis 
showed that, ADC ≤ 1.2 x 10-3 mm2/sec (OR = 
4.472, p = 0.008, 95CI%: 1.484-13.479) and 
fatty hilum absence (OR = 6.703, p = 0.011, 
95CI: 1.537-29.228%) were independent 
predictors for detecting axillary lymph node 
metastasis. 
We found a statistically significant difference 
between the mean ADC values of metastatic 
and benign lymph nodes (benign group mean 
ADC value: 1.31 ± 0.17, metastatic group mean 

















Table 3. Sensitivity, specificity, accuracy, positive predictive value, negative predictive values of 18F FDG 
PET/CT, MRI and 18F FDG PET/CT + MRI. 








































Figure 3. ROC curve demonstrating the success of 
MRI parameters in detecting axillary metastatic 
lymph nodes.  
 
 
Figure 4. Boxplot graph showing ADC values in 
metastatic and non-metastatic lymph nodes. 
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We evaluated the success of 18F FDG PET/CT 
in detecting axillary lymph nodes in113 
patients with univariate logistic regression 
analysis. The parameters, Tsize (OR = 1.068 p  
= 0.002, 95CI 1.025-1.113%), MTV (OR = 
1.082, p = 0.034, 95CI 1.006-1.163%), 18F 
FDG PET/CT-multifocality (OR = 2.625, p = 
0.036, 95CI 1.063-6.478%), LnDPET/CT (OR 
= 1.520, p < 0.001, 95CI%: 1.269-1.820), 
SUVmaxLn (OR = 2.213, p < 0.001, 95CI 
1.533-3.193) were statistically significant 
predictors in detecting axillary metastatic 
lymph nodes, whereas SUVmaxT (OR = 1.011, 
p = 0.608, 95 CI 0.969-1.055) was not a reliable 
indicator in univariate analysis. We performed 
ROC analysis to obtain optimal sensitivity and 
specificity values of SUVmaxLn in detecting 
axillary lymph node metastasis and determined 
the threshold value 2 for SUVmaxLn. We 
created the model with the Backward LR 
method for multivariate logistic regression by 
including the parameters at p < 0.2 as a result 
of univariate analysis. In the multivariate 
logistic regression analysis, among the 18F FDG 
PET/CT parameters, only SUVmaxLn>2 (OR = 
33.077, p < 0.001, 95CI%: 10.911-100.270) 
was an independent predictor in detecting 
axillary metastatic lymph nodes. 
We included DCE-DWI MRI and 18F FDG 
PET/CT parameters with p <0.2 in the 
multivariate analysis as a result of univariate 
analysis. Multivariate logistic regression 
analysis showed that, ADC ≤ 1.2 x 10-3 mm2/sec 
(OR = 6.665, p = 0.001, 95CI%: 2.181-20.370) 
and LnSUVmax > 2 (OR = 15.2, p < 0.001, 
95CI%: 4.587-50.376) were independent 
predictors in detecting axillary metastatic 
lymph nodes. The sensitivity of SUVmaxLn > 
2 was 73.7%, with a specificity of 92.7 (AUC = 
0.845, p < 0.001). For ADC ≤ 1.21.2 x 10-3 
mm2/sec, sensitivity was 74% and specificity 




















We performed Cohen’s kappa analysis between 
visual analysis results of 18F FDG PET/CT and 
MRI. We observed a satisfactory value of 
agreement between the modalities (kappa: 
0.669, p < 0.001). We also found a good 
agreement between the total result of MRI + 18F 
FDG PET/CT visual evaluation and 




In this study, we visually and quantitatively 
evaluated the success of using 18F FDG 
PET/CT, (DCE+DWI) MRI and a combination 
of them in detecting axillary lymph node 
metastasis in patients with newly diagnosed 
breast cancer. 
In the visual analysis, we found a sensitivity of 
78% and a specificity of 94% for 18F FDG 
PET/CT; a sensitivity of 70% and a specificity 
of 96% for MRI. In the meta-analysis of 21 
studies in 1,905 patients, the sensitivity of 18F 
FDG PET/CT was 40 to 89% (pooled 64%), 
 
Figure 5. ROC curve showing success in detecting 
the presence of axillary lymph node metastasis for 
SUVmaxLn > 2 and ADC ≤ 1.2 x 10-3mm2/sec. 
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with a specificity of 84 to 94% (pooled 93%). 
The sensitivity of MRI was 40 to100% (pooled: 
82%), with a specificity of 44 to100% (pooled 
94%) [18]. We observed an increase in 
sensitivity and specificity values when MRI 
and 18F FDG PET/CT were used together 
(sensitivity: 83.8%, specificity: 98%). In 
another study in which 215 patients were 
evaluated, the total sensitivity of MRI and 18F 
FDG PET/CT used together was 72.3, with a 
specificity of 92.4. Higher sensitivity and 
specificity values were obtained when used 
together than when used separately (sensitivity 
and specificity for MRI: 67.5 and 78%, for 18F 
FDG PET/CT: 62.7 and 88.6%) [19]. 
Primary tumour MTV, Tsize, multifocality, 
LnDPET/CT, SUVmaxLn were statistically 
significant 18F FDG PET/CT parameters for the 
presence of axillary lymph node metastasis in 
the univariate analysis. In the multivariate 
analysis, only SUVmaxLn was an independent 
parameter for the presence of axillary lymph 
node metastasis. In a study with 173 patients, 
only MTV was associated with the presence of 
axillary lymph node metastasis in T2 and T3 
tumours, while MTV in T1 tumours was not 
associated with axillary lymph node metastasis 
[20]. In another study, only total lesion 
glycolysis (TLG) was an independent marker 
for the presence of axillary lymph node 
metastasis among primary tumour parameters 
[21]. In a study with 671 patients who were 
classified according to receptor subtypes as ER-
positive/HER2-negative and HER2-positive, 
primary tumour SUVmax (> 4.25) and tumour 
size was associated with the presence of 
axillary lymph node metastasis. In patients of 
the triple negative (TN) receptor subgroup, 
primary tumour characteristics were not 
associated with the presence of axillary lymph 
node metastasis [22]. When we determined a 
threshold value of 2 for SUVmaxLn, we found 
a sensitivity of 73.7%, and a specificity of 
92.7%. In a study that included 196 patients, 
axillary lymph node SUVmax was associated 
with metastasis; when the authors took 
SUVmax threshold value as “1”, they found a 
sensitivity of 53.8% and a specificity of 93.9% 
[23]. 
In this study, ADC values of metastatic axillary 
lymph nodes were lower than those of non-
metastatic lymph nodes, similar to previous 
findings [16, 24]. For an ADC value of 1.2 x 10-
3 mm2/sec, we found satisfactory values of 
sensitivity and specificity in detecting axillary 
lymph node metastasis. In a study involving 
110 patients, the authors found a threshold 
value of 0.90 x 10-3 mm2/sec for ADC, with a 
sensitivity of 100% and a specificity of 83.3%. 
We assumed that one of the reason for this 
difference may be the fact that not all of the 
patients’ imaging was performed with 3T MRI 
[24]. In another study performed with 3Tesla 
MRI in 52 patients, the sensitivity was 72.4% 
and the specificity was 79.6% for the ADC 
value of 0.812 x 10-3 mm2/sec. [25]. 
We found a significant relationship between the 
absence of fatty hilum in lymph nodes and the 
presence of axillary lymph node metastasis. In 
a study with 56 patients, the authors found a 
significant relationship between the absence of 
fatty hilum in lymph nodes and metastasis [26]. 
The main limitation of our study is that it is 
single-centred and retrospective. Although all 
our patients had IDC, we the patient group was 
not enough to analyse according to the hormone 
receptor status. We could not assess the cortical 
thickness parameter of the lymph nodes 
although it was an important criterion for 
axillary lymph node metastasis. 
In conclusion, LnSUVmax>2 and ADC≤1.2 x 
10-3 mm2/sec were independent predictors in 
detecting axillary lymph node metastasis in 
patients with newly diagnosed breast cancer. 
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